| 1.1 Smoking cessation |
4 |
1924 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.53 [1.21, 1.93] |
| 1.2 Adverse events |
2 |
485 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.98 [0.80, 1.19] |
| 1.2.1 4 weeks |
1 |
29 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.74 [0.31, 1.73] |
| 1.2.2 6 months |
1 |
456 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.81, 1.22] |
| 1.3 Serious adverse events |
3 |
1183 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.44 [0.94, 2.19] |
| 1.3.1 4 weeks |
1 |
29 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 1.3.2 1 year |
1 |
698 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.37 [0.77, 2.41] |
| 1.3.3 6 months |
1 |
456 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.53 [0.81, 2.88] |
| 1.4 Carbon monoxide (ppm) |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.4.1 8 weeks |
2 |
136 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.66 [‐1.94, 0.62] |
| 1.5 Heart rate (bpm) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.5.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.6 Systolic blood pressure |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.6.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.7 Blood oxygen saturation |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.7.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.8 3‐HPMA (pmol/mg creatinine) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.8.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.9 NNAL (pmol/mg creatinine)) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.9.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.10 2‐HPMA (pmol/mg creatinine) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.10.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.11 HMPMA (pmol/mg creatinine) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.11.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.12 PheT (pmol/mg creatinine) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.12.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.13 CEMA (pmol/mg creatinine) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.13.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.14 AAMA (pmol/mg creatinine) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.14.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.15 FEV1 (ml) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.15.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.16 FEV1/FVC (%) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.16.1 8 weeks |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 1.17 Product use at 6+ months |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
